Orion Oyj
ORNBV.HEDrugs in Pipeline
18
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
Asthma
Midazolam
Continuous Sedation in Initially Sedated Adults in ICU
Ibuprofen
Pain
Dexmedetomidine
Continuous Sedation in Initially Sedated Adults in ICU
levosimendan
Coronary Heart Disease
ORM-12741
Alzheimer's Disease
Stalevo
Parkinson's Disease
Tasipimidine
Insomnia
Carbidopa
Parkinson's Disease
ODM-209
Prostate Cancer Metastatic
ODM-212
Mesothelioma
budesonide and formoterol 200/6 microg
Asthma
ODM-208
Prostate Cancer Metastatic
ODM-207
Solid Tumors
ODM-101 65mg Carbidopa
Parkinson's Disease
ODM-109
Amyotrophic Lateral Sclerosis
ODM-204
Prostate Cancer
ODM-201
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh | Phase 3 | Asthma | - | - |
Midazolam | Phase 3 | Continuous Sedation in Initially Sedated Adults in ICU | - | - |
Ibuprofen | Phase 3 | Pain | - | - |
Dexmedetomidine | Phase 3 | Continuous Sedation in Initially Sedated Adults in ICU | - | - |
levosimendan | Phase 3 | Coronary Heart Disease | - | - |
ORM-12741 | Phase 2 | Alzheimer's Disease | - | - |
Stalevo | Phase 2 | Parkinson's Disease | - | - |
Tasipimidine | Phase 2 | Insomnia | - | - |
Carbidopa | Phase 2 | Parkinson's Disease | - | - |
ODM-209 | Phase 2 | Prostate Cancer Metastatic | - | - |
ODM-212 | Phase 2 | Mesothelioma | - | - |
budesonide and formoterol 200/6 microg | Phase 2 | Asthma | - | - |
ODM-208 | Phase 2 | Prostate Cancer Metastatic | - | - |
ODM-207 | Phase 2 | Solid Tumors | - | - |
ODM-101 65mg Carbidopa | Phase 2 | Parkinson's Disease | - | - |
ODM-109 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
ODM-204 | Phase 2 | Prostate Cancer | - | - |
ODM-201 | Phase 2 | Prostate Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Orion Oyj's drug pipeline?→
CatalystAlert tracks 18 drug candidates in Orion Oyj's (ORNBV.HE) pipeline across Phase 3, Phase 2. Its lead program is Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Orion Oyj's next FDA catalyst?→
Orion Oyj's (ORNBV.HE) next tracked catalyst is a Phase 2 expected July 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ORNBV.HE biotech catalysts?→
Add ORNBV.HE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Orion Oyj's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.